指南与共识生殖医学

循证指南:不明原因不孕†

Evidence-based guideline: unexplained infertility†.
指南 / 共识 · Hum Reprod · 2023-01-01

该指南由欧洲人类生殖与胚胎学会(ESHRE)按结构化方法制定,检索截至2022年10月24日的英文文献,针对不明原因不孕(UI)的定义、诊断和治疗给出52条推荐。UI为排除性诊断,一线治疗被认为是宫腔内人工授精(IUI)联合卵巢刺激;证据基于的推荐中无高质量证据支持,多数为极低质量证据。

要点

  • UI为排除性诊断,指南概述了不孕检查中夫妇应/可接受的基础诊断流程。
  • UI夫妇的一线治疗被认为是IUI联合卵巢刺激。
  • 52条推荐中40条为循证推荐(29条强推荐、11条弱推荐),10条良好实践要点,2条仅研究推荐。

核心结论

  • 该指南旨在帮助临床医生为不明原因不孕(UI)夫妇提供最佳诊疗,并给出52条关于UI定义、诊断和治疗的推荐。

研究设计与样本

  • 指南按ESHRE结构化方法制定,由专家组提出关键问题后开展文献检索与评估,纳入截至2022年10月24日发表的英文论文。
  • 推荐经指南制定组(GDG)讨论至达成共识,初稿经利益相关方评议后由GDG和ESHRE执行委员会批准最终版。

主要发现

  • 52条推荐中,40条为循证推荐(29条强推荐、11条弱推荐),10条良好实践要点,2条仅研究推荐。
  • 循证推荐中无高质量证据支持,1条为中等质量证据,9条为低质量证据,31条为极低质量证据。
  • UI为排除性诊断,指南概述了不孕检查中夫妇应/可接受的基础诊断流程,并探讨了额外检查的必要性。
  • UI夫妇的一线治疗被认为是IUI联合卵巢刺激,指南还评估了其他附加和替代治疗选择。

关键数值与推荐

  • UI夫妇的一线治疗被认为是IUI联合卵巢刺激。
  • 指南给出52条推荐:40条循证推荐(29条强推荐、11条弱推荐)、10条良好实践要点、2条仅研究推荐。
  • 循证推荐证据质量:无高质量证据,1条中等质量,9条低质量,31条极低质量。

临床怎么用

  • 指南为临床医生提供基于当前最佳证据的UI夫妇诊疗清晰建议。
  • 指南还提供研究推荐清单以促进该领域进一步研究,完整指南和患者手册见www.eshre.eu/guideline/UI。

局限性

  • UI夫妇的大多数额外诊断检查和干预未经严格评估。
  • 对其中很大一部分检查和治疗,证据非常有限且质量极低。
  • 需要更多证据,未来研究结果可能导致当前推荐被修订。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the recommended management for couples presenting with unexplained infertility (UI), based on the best available evidence in the literature? SUMMARY ANSWER: The evidence-based guideline on UI makes 52 recommendations on the definition, diagnosis, and treatment of UI. WHAT IS KNOWN ALREADY: UI is diagnosed in the absence of any abnormalities of the female and male reproductive systems after 'standard' investigations. However, a consensual standardization of the diagnostic work-up is still lacking. The management of UI is traditionally empirical. The efficacy, safety, costs, and risks of treatment options have not been subjected to robust evaluation. STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the structured methodology for ESHRE guidelines. Following formulation of key questions by a group of experts, literature searches, and assessments were undertaken. Papers written in English and published up to 24 October 2022 were evaluated. PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on the available evidence, recommendations were formulated and discussed until consensus was reached within the guideline development group (GDG). Following stakeholder review of an initial draft, the final version was approved by the GDG and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: This guideline aims to help clinicians provide the best care for couples with UI. As UI is a diagnosis of exclusion, the guideline outlined the basic diagnostic procedures that couples should/could undergo during an infertility work-up, and explored the need for additional tests. The first-line treatment for couples with UI was deemed to be IUI in combination with ovarian stimulation. The place of additional and alternative options for treatment of UI was also evaluated. The GDG made 52 recommendations on diagnosis and treatment for couples with UI. The GDG formulated 40 evidence-based recommendations-of which 29 were formulated as strong recommendations and 11 as weak-10 good practice points and two research only recommendations. Of the evidence-based recommendations, none were supported by high-quality evidence, one by moderate-quality evidence, nine by low-quality evidence, and 31 by very low-quality evidence. To support future research in UI, a list of research recommendations was provided. LIMITATIONS, REASONS FOR CAUTION: Most additional diagnostic tests and interventions in couples with UI have not been subjected to robust evaluation. For a large proportion of these tests and treatments, evidence was very limited and of very low quality. More evidence is required, and the results of future studies may result in the current recommendations being revised. WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides clinicians with clear advice on best practice in the care of couples with UI, based on the best evidence currently available. In addition, a list of research recommendations is provided to stimulate further studies in the field. The full guideline and a patient leaflet are available in www.eshre.eu/guideline/UI. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed by ESHRE, who funded the guideline meetings, literature searches, and dissemination of the guideline in collaboration with the Monash University led Australian NHMRC Centre of Research Excellence in Women's Health in Reproductive Life (CREWHIRL). The guideline group members did not receive any financial incentives; all work was provided voluntarily. D.R. reports honoraria from IBSA and Novo Nordisk. B.A. reports speakers' fees from Merck, Gedeon Richter, Organon and Intas Pharma; is part of the advisory board for Organon Turkey and president of the Turkish Society of Reproductive Medicine. S.B. reports speakers' fees from Merck, Organon, Ferring, the Ostetric and Gynaecological Society of Singapore and the Taiwanese Society for Reproductive Medicine; editor and contributing author, Reproductive Medicine for the MRCOG, Cambridge University Press; is part of the METAFOR and CAPE trials data monitoring committee. E.B. reports research grants from Roche diagnostics, Gedeon Richter and IBSA; speaker's fees from Merck, Ferring, MSD, Roche Diagnostics, Gedeon Richter, IBSA; E.B. is also a part of an Advisory Board of Ferring Pharmaceuticals, MSD, Roche Diagnostics, IBSA, Merck, Abbott and Gedeon Richter. M.M. reports consulting fees from Mojo Fertility Ltd. R.J.N. reports research grant from Australian National Health and Medical Research Council (NHMRC); consulting fees from Flinders Fertility Adelaide, VinMec Hospital Hanoi Vietnam; speaker's fees from Merck Australia, Cadilla Pharma India, Ferring Australia; chair clinical advisory committee Westmead Fertility and research institute MyDuc Hospital Vietnam. T.P. is a part of the Research Council of Finland and reports research grants from Roche Diagnostics, Novo Nordics and Sigrid Juselius foundation; consulting fees from Roche Diagnostics and organon; speaker's fees from Gedeon Richter, Roche, Exeltis, Organon, Ferring and Korento patient organization; is a part of NFOG, AE-PCOS society and several Finnish associations. S.S.R. reports research grants from Roche Diagnostics, Organon, Theramex; consulting fees from Ferring Pharmaceuticals, MSD and Organon; speaker's fees from Ferring Pharmaceuticals, MSD/Organon, Besins, Theramex, Gedeon Richter; travel support from Gedeon Richter; S.S.R. is part of the Data Safety Monitoring Board of TTRANSPORT and deputy of the ESHRE Special Interest Group on Safety and Quality in ART; stock or stock options from IVI Lisboa, Clínica de Reprodução assistida Lda; equipment/medical writing/gifts from Roche Diagnostics and Ferring Pharmaceuticals. S.K.S. reports speakers' fees from Merck, Ferring, MSD, Pharmasure. HRV reports consulting and travel fees from Ferring Pharmaceuticals. The other authors have nothing to disclose. DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. (Full disclaimer available at www.eshre.eu/guidelines.).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Romualdi D, Ata B, Bhattacharya S, et al. Evidence-based guideline: unexplained infertility†. Hum Reprod. 2023. PMID: 37599566. doi:10.1093/humrep/dead150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。